

SIFR - predictive ex vivo gut microbiome simulation

Commonly used acronym: SIFR

Created on: 07-06-2023 - Last modified on: 08-06-2023

SCOPE OF THE METHOD

The Method relates to	Animal health, Human health
The Method is situated in	Basic Research, Translational - Applied Research
Type of method	In vitro - Ex vivo
This method makes use of	Animal derived cells / tissues / organs

DESCRIPTION

Method keywords

gut microbiota

metabolomics

metagenomics

screening

mechanism of action

gut health

predictivity

humans

Scientific area keywords

fibre

probiotic

prebiotic

postbiotic

api

drug-bug interaction

host-microbiome interaction

inter-individual variability

IBD

pathogen

digestion

colonic fermentation

kinetics

Method description

The Systemic Intestinal Fermentation Research technology, SIFR in short, is a uniquely validated simulation of gut microbial ecosystems, shown to be predictive for clinical outcomes. The SIFR can simulate a wide variety of gut microbiota from humans (infants, adults, elderly; healthy, diseased) to animals (pig, poultry, cat & dog). Working *ex vivo* (maintaining the integrity of the gut microbiome during the investigation) and integrating robotics for a high throughput, this versatile technology can address early and late preclinical needs: screening and in-depth mechanistic characterisation. Each study addresses interindividual variability in the target population.

Lab equipment

Method status

History of use

Internally validated

Published in peer reviewed journal

PROS, CONS & FUTURE POTENTIAL

Advantages

- Validated to be predictive for clinical outcomes
- Can address simultaneously a wide array of analytics: compositional, metabolic, host-microbiome interactions, fingerprinting...
- Gets rid of *in vitro* bias
- Embraces biological variation
- High-throughput and technically robust thanks to automation

Modifications

The SIFR is modular: pre-digestion, mucosal simulation, host-microbiome module.

REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION

References

Van den Abbeele P, Deyaert S, Thabuis C, Perreau C, Bajic D, Wintergerst E, Joossens M, Firman J, Walsh D and Baudot A (2023) Bridging preclinical and clinical gut microbiota research using the ex vivo SIFR® technology. *Front. Microbiol.* 14:1131662. doi: 10.3389/fmicb.2023.1131662

Van den Abbeele, P.; Deyaert, S.; Albers, R.; Baudot, A.; Mercenier, A. Carrot RG-I Reduces Interindividual Differences between 24 Adults through Consistent Effects on

Gut Microbiota Composition and Function Ex Vivo. *Nutrients* 2023, 15, 2090.
<https://doi.org/10.3390/nu15092090>

Bajic, D.; Wiens, F.; Wintergerst, E.; Deyaert, S.; Baudot, A.; Van den Abbeele, P. HMOs Exert Marked Bifidogenic Effects on Children's Gut Microbiota Ex Vivo, Due to Age-Related Bifidobacterium Species Composition. *Nutrients* 2023, 15, 1701.
<https://doi.org/10.3390/nu15071701>

Van den Abbeele, P.; Goggans, M.; Deyaert, S.; Baudot, A.; Van de Vliet, M.; Calatayud Arroyo, M.; Lelah, M. Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo. *Int. J. Mol. Sci.* 2023, 24, 5859.
<https://doi.org/10.3390/ijms24065859>

Van den Abbeele, P.; Detzel, C.; Rose, A.; Deyaert, S.; Baudot, A.; Warner, C. Serum-Derived Bovine Immunoglobulin Stimulates SCFA Production by Specific Microbes in the Ex Vivo SIFR® Technology. *Microorganisms* 2023, 11, 659.
<https://doi.org/10.3390/microorganisms11030659>

Associated documents

[2023 - SIFR validation.pdf](#)

PARTNERS AND COLLABORATIONS

Organisation

Name of the organisation Cryptobiotix

Department Cryptobiotix

Country Belgium

Coordinated by



Financed by

